Exelixis | Sustainability Performance

https://www.exelixis.com

Exelixis is focused on the discovery, development, and commercialization of cancer treatments. The company works on advancing therapies aimed at addressing unmet medical needs in oncology, emphasizing innovation and improving patient outcomes.

1994

United States

1,001 - 5,000 employees

Biotechnology

$1B - 10B in revenue

$500M - 1B in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#8559

Overall

#1936

in United States

#181

in Biotechnology

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Beyond Top 100

Overview

Environmental

Digital emissionsEnergy consumptionNature and biodiversityClimate risk

Social

Diversity and InclusionPay GapsExternalities

Governance

TargetsSDG ImpactESG scores and Exclusions

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Arcturus Therapeutics

United States, Hospital & Health Care, Biotechnology

NeueHealth

United States, Hospital & Health Care, Hospital & Health Care

Envista

United States, Hospital & Health Care, Medical Device

Female employees

50% 2024

Laggard

Externalities

434.9K $, 2024

Leading

Market cap

16.6B $, 2026▲31.3% YoY

Revenue

2.3B $, 2025▲6.5% YoY

R&D intensity

35.56% 2025

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Exelixis has faced multiple US patent disputes over its Cabometyx kidney cancer drug including the controversial 2022 MSN Pharmaceuticals generic challenge, plus periodic class actions over inadequate disclosure of clinical trial results affecting share price.

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Exelixis has faced multiple US patent disputes over its Cabometyx kidney cancer drug including the controversial 2022 MSN Pharmaceuticals generic challenge, plus periodic class actions over inadequate disclosure of clinical trial results affecting share price.

Exelixis | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable electricity

Female employees

Digital Emissions

Controversy level

Climate risk

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Land use

Diversity & inclusion

Pay gap breakdown

Externalities

Revenue & EBITDA

Revenue by region

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

Overall score

Environment

Social

Governance

Exclusion screening

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Exelixis | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Renewable electricity

Female employees

Digital Emissions

Controversy level

Climate risk

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Land use

Diversity & inclusion

Pay gap breakdown

Externalities

Revenue & EBITDA

Revenue by region

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

Overall score

Environment

Social

Governance

Exclusion screening

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package